Overview Dividends

(CORT) Corcept Therapeutics - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US2183521028

Hyperglycemia, Cushings, Relacorilant, Dazucorilant, Miricorilant

EPS (Earnings per Share)

EPS Growth (3y CAGR): 4.98%
EPS Trend (3y Corr): 23.0%

Last SUE: 0.33σ
Qual. Beats: 0

Revenue

Revenue Growth (3y CAGR): 29.01%
Revenue Trend (3y Corr): 95.9%

Last SUE: -0.91σ
Qual. Beats: 0

Risk via 10d forecast
Volatility	54.8%
Value at Risk 5%th	70.2%
Relative Tail Risk	-22.13%

Reward TTM
Sharpe Ratio	0.68
Alpha	22.34

Character TTM
Hurst Exponent	0.376
Beta	1.256
Beta Downside	1.394

Drawdowns 3y
Max DD	45.51%
Mean DD	18.56%
Median DD	17.14%

Description: CORT Corcept Therapeutics November 03, 2025

Corcept Therapeutics (NASDAQ:CORT) is a U.S.-based biopharma focused on developing and commercializing medicines for severe endocrine-related disorders. Its only FDA-approved product, Korlym (mifepristone), treats hyperglycemia secondary to endogenous Cushing’s syndrome in adults who are ineligible for or have failed surgery. The pipeline spans multiple phases: relacorilant is in Phase III for hypercortisolism and in a separate Phase III trial combined with nab-paclitaxel for platinum-resistant ovarian cancer; early-stage programs target adrenal cancer, prostate cancer, ALS (dazucorilant, Phase II), and metabolic-dysfunction-associated steatohepatitis (miricorilant, Phase IIb).

Key quantitative points as of the latest filing: Korlym generated roughly $71 million in net sales in FY 2023, representing about 85 % of total revenue, while cash and short-term investments stood at $210 million, giving the company a runway of over two years at current burn rates. The global Cushing’s syndrome market is estimated at $1.2 billion and is projected to grow ~5 % CAGR, driven by increased diagnostic awareness and limited therapeutic options-an environment that could amplify Korlym’s market share if relacorilant succeeds. Additionally, biotech sector funding remains robust, with Q3 2024 venture capital inflows up 12 % YoY, supporting continued R&D investment for companies like Corcept.

If you want a data-driven deep-dive into CORT’s valuation assumptions and scenario analysis, ValueRay’s research platform offers tools that can help you quantify the upside and downside risks.

CORT Stock Overview

Market Cap in USD	7,968m
Sub-Industry	Pharmaceuticals
IPO / Inception	2004-04-14
Return 12m vs S&P 500	25.7%
Analyst Rating	4.50 of 5

CORT Dividends

Currently no dividends paid

CORT Growth Ratios

Metric	Value
CAGR 3y	42.82%
CAGR/Max DD Calmar Ratio	0.94
CAGR/Mean DD Pain Ratio	2.31
Current Volume	471k
Average Volume	598k

Piotroski VR‑10 (Strict, 0-10) 5.5

Net Income (105.2m TTM) > 0 and > 6% of Revenue (6% = 44.5m TTM)

FCFTA 0.20 (>2.0%) and ΔFCFTA 1.56pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 49.77% (prev 54.21%; Δ -4.45pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.20 (>3.0%) and CFO 162.8m > Net Income 105.2m (YES >=105%, WARN >=100%)

Net Debt (-118.8m) to EBITDA (72.5m) ratio: -1.64 <= 3.0 (WARN <= 3.5)

Current Ratio 3.14 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (119.4m) change vs 12m ago 5.03% (target <= -2.0% for YES)

Gross Margin 98.19% (prev 98.44%; Δ -0.25pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 92.19% (prev 80.15%; Δ 12.05pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -3.94 (EBITDA TTM 72.5m / Interest Expense TTM -17.9m) >= 6 (WARN >= 3)

Altman Z'' 9.38

(A) 0.45 = (Total Current Assets 541.1m - Total Current Liabilities 172.3m) / Total Assets 823.6m

(B) 0.75 = Retained Earnings (Balance) 619.1m / Total Assets 823.6m

(D) 3.24 = Book Value of Equity 621.6m / Total Liabilities 191.7m

Total Rating: 9.38 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 67.97

1. Piotroski 5.50pt = 0.50

2. FCF Yield 2.15% = 1.08

3. FCF Margin 21.93% = 5.48

4. Debt/Equity 0.01 = 2.50

5. Debt/Ebitda -1.64 = 2.50

6. ROIC - WACC (= -3.01)% = -3.77

7. RoE 15.99% = 1.33

8. Rev. Trend 95.88% = 7.19

9. EPS Trend 22.98% = 1.15

What is the price of CORT shares?

As of November 19, 2025, the stock is trading at USD 75.11 with a total of 471,036 shares traded.
Over the past week, the price has changed by -4.94%, over one month by -4.44%, over three months by +4.67% and over the past year by +42.74%.

Is CORT a buy, sell or hold?

Corcept Therapeutics has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy CORT.

Strong Buy: 2
Buy: 2
Hold: 0
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the CORT price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	135.3	80.1%
Analysts Target Price	135.3	80.1%
ValueRay Target Price	99.1	31.9%

CORT Fundamental Data Overview November 17, 2025

Market Cap USD = 7.97b (7.97b USD * 1.0 USD.USD)
P/E Trailing = 86.8276
P/E Forward = 34.6021
P/S = 10.7506
P/B = 12.5746
P/EG = 0.61
Beta = 0.2
Revenue TTM = 741.2m USD
EBIT TTM = 70.6m USD
EBITDA TTM = 72.5m USD
Long Term Debt = 6.36m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 1.05m USD (from shortTermDebt, last quarter)
Debt = 6.36m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -118.8m USD (from netDebt column, last quarter)
Enterprise Value = 7.55b USD (7.97b + Debt 6.36m - CCE 421.7m)
Interest Coverage Ratio = -3.94 (Ebit TTM 70.6m / Interest Expense TTM -17.9m)
FCF Yield = 2.15% (FCF TTM 162.6m / Enterprise Value 7.55b)
FCF Margin = 21.93% (FCF TTM 162.6m / Revenue TTM 741.2m)
Net Margin = 14.19% (Net Income TTM 105.2m / Revenue TTM 741.2m)
Gross Margin = 98.19% ((Revenue TTM 741.2m - Cost of Revenue TTM 13.4m) / Revenue TTM)
Gross Margin QoQ = 97.79% (prev 98.23%)
Tobins Q-Ratio = 9.17 (Enterprise Value 7.55b / Total Assets 823.6m)
Interest Expense / Debt = 56.32% (Interest Expense 3.58m / Debt 6.36m)
Taxrate = 29.03% (4.42m / 15.2m)
NOPAT = 50.1m (EBIT 70.6m * (1 - 29.03%))
Current Ratio = 3.14 (Total Current Assets 541.1m / Total Current Liabilities 172.3m)
Debt / Equity = 0.01 (Debt 6.36m / totalStockholderEquity, last quarter 631.9m)
Debt / EBITDA = -1.64 (Net Debt -118.8m / EBITDA 72.5m)
Debt / FCF = -0.73 (Net Debt -118.8m / FCF TTM 162.6m)
Total Stockholder Equity = 657.6m (last 4 quarters mean from totalStockholderEquity)
RoA = 12.77% (Net Income 105.2m / Total Assets 823.6m)
RoE = 15.99% (Net Income TTM 105.2m / Total Stockholder Equity 657.6m)
RoCE = 10.63% (EBIT 70.6m / Capital Employed (Equity 657.6m + L.T.Debt 6.36m))
RoIC = 7.62% (NOPAT 50.1m / Invested Capital 657.6m)
WACC = 10.63% (E(7.97b)/V(7.97b) * Re(10.64%) + (debt cost/tax rate unavailable))
Discount Rate = 10.64% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 3.79%
[DCF Debug] Terminal Value 70.81% ; FCFE base≈154.6m ; Y1≈167.3m ; Y5≈207.7m
Fair Price DCF = 22.68 (DCF Value 2.39b / Shares Outstanding 105.2m; 5y FCF grow 9.27% → 3.0% )
EPS Correlation: 22.98 | EPS CAGR: 4.98% | SUE: 0.33 | # QB: 0
Revenue Correlation: 95.88 | Revenue CAGR: 29.01% | SUE: -0.91 | # QB: 0

Additional Sources for CORT Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle